Sustained unresponsiveness in peanut oral immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Association of cytotoxic effector memory CD8Allergy · 2025
   Article
2. Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023
   Article
3. Addressing Common Misconceptions in Food Allergy: A Review.Children (Basel, Switzerland) · 2021
   Review
4. Grand Challenges in Food Allergy.Frontiers in allergy · 2021
   Article
5. Oral immunotherapy for peanut allergy: The con argument.The World Allergy Organization journal · 2020
   Review

Corrections and comments

• Comment on
  Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as